A Multicenter Phenotype-Genotype Analysis of DM1 Patients in China
Launched by HUASHAN HOSPITAL · Oct 20, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a multicenter-based, prospective, observational study that primarily focuses on the diagnosis and progression of DM1 patients in China. The investigators collect patient data, including basic information, strength evaluations, genetic data, electromyography results, cognitive performance, and MRIs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18-80 years
- • With enough cognitivie ability to understand the content and sign the informed consent form
- • With CTG repeats \>50 in DMPK gene, revealed by PCR test
- Exclusion Criteria:
- • Patients with severe mental illness, or severe anxiety and depression
- • With comorbidities such as traumatic brain injury and cranial tumors
- • A history of alcoholism, psychotropic substance abuse, etc.
- • Patients with severe medical conditions and unstable vital signs that cannot tolerate the tests.
- • Female in pregnancy
About Huashan Hospital
Huashan Hospital, affiliated with Fudan University in Shanghai, is a leading medical institution renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, Huashan Hospital leverages its extensive expertise in various medical disciplines to advance the development of new therapies and treatment modalities. The hospital's state-of-the-art facilities and multidisciplinary teams facilitate rigorous clinical investigations, ensuring adherence to ethical standards and regulatory compliance. With a focus on improving patient outcomes, Huashan Hospital actively collaborates with academic and industry partners to drive forward-thinking research initiatives that address critical healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Chongbo Zhao, PhD
Study Director
Huashan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported